Related Experiment Video
Updated: May 3, 2026

Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
The role of angiopoietin-1 in kidney disease
1Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea.
Abstract:
Injury to the renal microvasculature and inflammatory process may be major factors in the progression of renal disease, therefore, protection of the renal endothelial cell and regulation of inflammatory process may be an important therapeutic target of renal disease. Thus, we evaluated the protective effect of cartilage oligomeric matrix protein-angiopoietin-1 (COMP-Ang1) in unilateral ureteral obstruction (UUO)-induced renal fibrosis, cyclosporine A (CsA)-induced renal injury, and the diabetic nephropathy model. In the UUO model, morphologic examination indicated less tubular injury and tubulointerstitial fibrosis in mice that received COMP-Ang1 compared to vehicle-treated mice. Interstitial type I collagen, myofibroblast accumulation, renal surface microvasculature and renal blood flow were higher after treatment with COMP-Ang1 compared to vehicle-treated mice. COMP-Ang1 treatment decreased monocyte/macrophage infiltration, tissue levels of transforming growth factor β1, and Smad 2/3 phosphorylation and increased Smad 7 in the obstructed kidney. In CsA-induced renal injury, histologic examination showed significantly decreased CsA-induced tubular damage and tubulointerstitial fibrosis in COMP-Ang1 treated mice. COMP-Ang1 administration also decreased increased macrophage infiltration, adhesion molecule expression, TGF-β1, and Smad 2/3 levels in CsA-treated kidneys, while increasing Smad 7 levels. Laser-Doppler sonographic findings and endothelial factor VIII staining revealed that COMP-Ang1 had a preservative effect on peritubular vasculature. In the diabetic nephropathy model, COMP-Ang1 reduced albuminuria and decreased mesangial expansion, thickening of the glomerular basement membrane and podocyte foot process broadening and effacement. COMP-Ang1 may delay the fibrotic changes in the kidney of diabetic db/db mice through its anti-inflammatory or metabolic effects. In conclusion, COMP-Ang1 may be an endothelium-specific and anti-inflammatory therapeutic modality in fibrotic renal disease.
Insights
Cartilage oligomeric matrix protein-angiopoietin-1 (COMP-Ang1) protects against kidney fibrosis and injury by reducing inflammation and preserving microvasculature. This therapeutic agent shows promise for treating fibrotic renal diseases.
Area of Science:
- Nephrology
- Vascular Biology
- Inflammation Research
Background:
- Renal microvascular injury and inflammation drive kidney disease progression.
- Protecting renal endothelial cells and managing inflammation are key therapeutic strategies.
- Cartilage oligomeric matrix protein-angiopoietin-1 (COMP-Ang1) is investigated for its protective effects.
Purpose of the Study:
- To evaluate the protective effects of COMP-Ang1 in established models of kidney disease.
- To assess COMP-Ang1's impact on renal fibrosis, injury, and inflammation.
- To determine COMP-Ang1's therapeutic potential in fibrotic renal conditions.
Main Methods:
- Utilized unilateral ureteral obstruction (UUO)-induced renal fibrosis model.
- Employed cyclosporine A (CsA)-induced renal injury model.
- Investigated COMP-Ang1 in a diabetic nephropathy model (db/db mice).
Main Results:
- COMP-Ang1 reduced tubular injury, tubulointerstitial fibrosis, and monocyte/macrophage infiltration in UUO and CsA models.
- COMP-Ang1 preserved renal microvasculature and blood flow, decreasing fibrotic markers like TGF-β1.
- In diabetic nephropathy, COMP-Ang1 lowered albuminuria and ameliorated glomerular changes.
Conclusions:
- COMP-Ang1 demonstrates significant protective effects against renal fibrosis and injury across multiple models.
- Its anti-inflammatory and endothelium-protective properties make it a potential therapeutic agent.
- COMP-Ang1 may offer a novel therapeutic strategy for fibrotic renal diseases.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Acute Kidney Injury II: Pathophysiology
Diabetic Nephropathy
Antihypertensive Drugs: Direct Renin Inhibitors
Acute Kidney Injury IV: Diagnostic Studies and Prevention

